Epsilon Healthcare Limited (ASX: EPN) is pleased to announce that the Company is now supplying a clinical study on the treatment of severe behavioural problems in youth with intellectual disability using cannabidiol medicines (the Trial) being conducted by Murdoch Children’s Research Institute (MCRI).
The Company is supplying MCRI with the study drug – a berry flavoured 30ml CBD100 product – at no cost and has developed a berry flavoured placebo for use in the study.
This trial is also supported by the Victorian Department of Health, who are providing a CBD isolate developed by IDT Australia to be used in the formulation of the study drug. This CBD Isolate was provided to the MCRI at no cost following an open tender process.
The Trial is a multi-centre, randomised, double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04821856). It is expected to occur over two years, with each participant to be involved for 10 weeks. MCRI will analyse the data independently and the results will be published in a peer-reviewed publication. In consideration for providing the study drug, the Company will receive a royalty-free licence to the study data generated from the Trial. MCRI will be the sole sponsor of the Trial.
Lead Investigator, Associate Professor Daryl Efron commented:
"We’re pleased to have Epsilon Healthcare support this clinical study by formulating and supplying the study drug and placebo. We look forward to working with them over the coming years on this study, as well as exploring opportunities in future studies.”
- Jarrod White, Chief Executive Officer of Epsilon
Read the full announcement.
To keep up to date with their news and progress, and for more information about healthcare as a whole, subscribe to Epsilon Healthcare's Chairman's List.